EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Real‐World Study on Unstable Parkinson's Disease: Levodopa Dosage Management and the Role of Nonmotor Symptoms

Fabrizio Stocchi iD, Jaime Kulisevsky, Wolfgang H Jost iD

Movement Disorders Clinical Practice · 2025-12 · 12 (12) · 2143-2153

DOI: 10.1002/mdc3.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 23.06.2025. Verfasst von Fabrizio Stocchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University San Raffaele Rome, Rome, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zambon SpA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD) is a neurodegenerative disorder associated with motor and nonmotor symptoms.

Objectives

This study assesses levodopa dose management, the therapeutic goals of clinicians, the factors that influence clinicians' choice of therapy, and the role of nonmotor symptoms using real‐world evidence from Germany, Italy, and Spain.

Methods

To assess the management of unstable PD patients on levodopa‐containing regimens, neurologists were asked to complete questionnaires (n = 181) and prospective electronic patient records (EPR) were collected (n = 2687). Neurologists were asked questions about their practice and approach to unstable PD patients. EPRs were completed by neurologists after each visit with patients, and the objectives of any changes to therapy were recorded.

Results

Seventy‐four percent of neurologists cited “improving motor symptoms” as the main objective for increasing daily levodopa dose. This was also the main objective when starting an add‐on (50%) and the main reason for selecting a new add‐on therapy (29%). In comparison, reducing nonmotor symptoms, depression, and pain was rarely cited as either the main or secondary objective for a therapy selection (15%, 9%, and 9%, respectively) even when over 60% of unstable patients had pain or depression and 29% had both. When the importance of add‐on therapy features was rated, “improve quality of life (QoL)” had the highest average score. Improving nonmotor symptoms, pain, and depression was among the lowest‐rated therapy feature.

Conclusions

These findings suggest that improving motor symptoms is a key driver of therapeutic choice. In prioritizing motor symptoms, neurologists may unintentionally neglect nonmotor symptoms, despite most patients suffering from pain or depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaAntiparkinson AgentsEuropeDepressionPrevalencePainHumansNeurologists

Stichwörter der Autor:innen

Parkinson's diseasedepressionlevodopapaintherapeutic goals

Substanzen

LevodopaAntiparkinson Agents

Autor:innen und Institutionen

  • Department of Neurology, University San Raffaele Rome, Rome, Italy.
  • Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele Rome, Rome, Italy.
  • Sant Pau Hospital, Universitat Autònoma de Barcelona and CIBERNED, Barcelona, Spain.
  • Parkinson-Klinik Ortenau, Wolfach, Germany.

ORCID-Profile: Fabrizio Stocchi, Wolfgang H Jost

Förderung

  • Zambon SpA

Zitieren

APA

Stocchi, F., Kulisevsky, J., & Jost, W. H. (2025). A Real‐World Study on Unstable Parkinson's Disease: Levodopa Dosage Management and the Role of Nonmotor Symptoms. Movement Disorders Clinical Practice, 12(12), 2143-2153. https://doi.org/10.1002/mdc3.70188

Vancouver

Stocchi F, Kulisevsky J, Jost WH. A Real‐World Study on Unstable Parkinson's Disease: Levodopa Dosage Management and the Role of Nonmotor Symptoms. Movement Disorders Clinical Practice. 2025;12(12):2143-2153. doi:10.1002/mdc3.70188

BibTeX
@article{Stocchi2025,
  author = {Stocchi, Fabrizio and Kulisevsky, Jaime and Jost, Wolfgang H},
  title = {A Real‐World Study on Unstable Parkinson's Disease: Levodopa Dosage Management and the Role of Nonmotor Symptoms},
  journal = {Movement Disorders Clinical Practice},
  year = {2025},
  volume = {12},
  number = {12},
  pages = {2143--2153},
  doi = {10.1002/mdc3.70188}
}
Kostenlos starten →